Considerations in the treatment of spasticity with intrathecal baclofen

American Journal of Health-System Pharmacy

Volumn 66, Issue 17 SUPPL. 5, 2009, Pages

  Mullarkey, Tamira ^a  

^a Saint Barnabas Health Care System   (United States)

Author keywords

Baclofen; Compounding; Control, quality; Diagnosis; Dosage; Drug administration routes; Muscle spasticity; Pharmacists; Quality of life; Skeletal muscle relaxants; Sterile products; Toxicity

Indexed keywords

BACLOFEN; BOTULINUM TOXIN; CLONIDINE; DANTROLENE; DIAZEPAM; TIZANIDINE;

ATAXIA; BRAIN; BRAIN INJURY; CARDIOVASCULAR DISEASE; CATHETER INFECTION; CEREBRAL PALSY; CONFERENCE PAPER; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG TOLERANCE; DRUG WITHDRAWAL; GRANULOMA; HEMATOMA; HUMAN; HYPERREFLEXIA; INFUSION PUMP; MULTIPLE SCLEROSIS; MUSCLE SPASM; MYALGIA; PATHOPHYSIOLOGY; PATIENT ASSESSMENT; PATIENT SAFETY; PATIENT SATISFACTION; PHYSIOTHERAPY; PRIORITY JOURNAL; QUALITY CONTROL; QUALITY OF LIFE; RESPIRATION DEPRESSION; SEDATION; SIDE EFFECT; SPASTICITY; SPINAL CORD; SPINAL CORD INJURY; STROKE; TRAUMATIC BRAIN INJURY; WITHDRAWAL SYNDROME;

EID: 69749114108     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp0108c     Document Type: Conference Paper

References (45)

1. Barnes MP. Management of spasticity. Age Ageing. 1998; 27:239-245
2. Centre for Neuro Skills. Brain injury glossary. www.neuroskills.com/ glossary.shtml (accessed 2008 Oct 22).
3. Exploring Spasticity. About spasticity. www.exploringspasticity.com/ exploringspasticity/explore/whatis.html (accessed 2009 Jan 2).
4. We Move. Profile of patients with spasticity. www.wemove.org/reports/ spasticity-2008.pdf (accessed 2009 Jan 5).
5. Wrong Diagnosis. Spasticity, www.wrongdiagnosis.com/s/spasticity/intro. htm (accessed 2008 Oct 22).
6. Weiss E, Lin D. Spasticity. In: Copper G, ed. Therapeutic uses of botulinum toxin. Totowa, NJ: Humana; 2007:7-18.
7. Baylor College of Medicine, Department of Neurosurgery. Definitions O-Z. www.bcm.edu/neurosurgery/defs/def-o-z.htm (accessed 2009 Jan 2).
8. Harben A. Spasticity symptoms and treatment. www.birf.info/home/library/ med-cond/mci-spassys.html (accessed 2009 Jan 2).
9. Moberg-Wolff EA. Spasticity. www.emedicine.com/pmr/topic177.htm (accessed 2008 Oct 23).
10. Apparelyzed. Spinal cord anatomy. www.apparelyzed.com/spinalcord.html (accessed 2008 Oct 22).
11. eMedicine. Spinal cord, topographical, and functional anatomy. www.emedicine.com/neuro/topic657.htm (accessed 2008 Oct 22).
12. Brown P. Pathophysiology of spasticity. J Neurol Neurosurg Psychiatry. 1994; 57:773-777
13. Vanek ZF. Spasticity. www.emedicine.com/neuro/topic706.htm (accessed 2008 Oct 22).
14. Mostoufi SA. Spasticity and its management. www.painmanagementrounds.org/ crus/painmanagement-2-5.pdf (accessed 2009 Jan 8).
15. Campbell WM, Ferrel A, McLaughlin JF et al. Long-term safety and efficacy of continuous intrathecal baclofen. Dev Med Child Neurol. 2002; 44:660-665 (Pubitemid 35230026)
16. Dario A, Tomei G. A benefit-risk assessment of baclofen in severe spinal spasticity. Drug Saf. 2004; 27:799-818. (Pubitemid 39243562)
17. Scheinberg A, Hall K, Lam LT et al. Oral baclofen in children with cerebral palsy: a double-blind cross-over pilot study. J Paediatr Child Health. 2006; 42:715-720 (Pubitemid 44581626)
18. Malanga G, Reiter RD, Garay E. Update on tizanidine for muscle spasticity and emerging indications. Expert Opin Pharmacother. 2008; 9:2209-2215
19. Gelber DA, Good DC, Dromerick A et al. Open-label dose-titration safety and efficacy study of tizanidine hydrochloride in the treatment of spasticity associated with chronic stroke. Stroke. 2001; 32:1841-1846 (Pubitemid 32772217)
20. Groves L, Shellenberger MK, Davis CS. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam. Adv Ther. 1998; 15:241-251 (Pubitemid 28454903)
21. Mathew A, Mathew MC. Bedtime diazepam enhances well-being in children with spastic cerebral palsy. Pediatr Rehabil. 2005; 8:63-66 (Pubitemid 40127954)
22. Botte MJ, Abrams RA, Bodine-Fowler SC. Treatment of acquired muscle spasticity using phenol peripheral nerve blocks. Orthopedics. 1995; 18:151-159
23. Simpson DM, Gracies JM, Graham HK et al. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008; 70:1691-1698 (Pubitemid 351644137)
24. Sadiq SA, Wang GC. Long-term intrathecal baclofen therapy in ambulatory patients with spasticity. J Neurol. 2006; 253:563-569
25. Deer TR, Raso LJ, Garten TG. Inflammatory mass of an intrathecal catheter in patients receiving baclofen as a sole agent: a report of two cases and a review of the identification and treatment of the complication. Pain Med. 2007; 8: 259-262
26. Guglielmino A, Sorbello M, Fazzio S et al. Continuous intrathecal baclofen administration by a fully implantable electronic pump for severe spasticity treatment: our experience. Minerva Anestesiol. 2006; 72:807-820 (Pubitemid 44650751)
27. Penn R. Intrathecal baclofen for spasticity of spinal origin: seven years experience. J Child Neurol. 1992; 77:236-240
28. Albright LA, Gilmartin R, Swift D et al. Long-term intrathecal baclofen therapy for severe spasticity of cerebral origin. J Neurosurg. 2003; 98:291-295 (Pubitemid 36151022)
29. Medtronic. ITB Therapy product monograph. Available through Medtronic, UC1999504316e EN NP2477e.
30. Laterra J, Goldstein GW. Appendix B: ventricular organization of cerebrospinal fluid: blood-brain barrier, brain edema, and hydrocephalus. In: Kandel ER, Schwartz JH, Jessell TM, eds. Principles of Neural Science. 4th ed. New York: McGraw-Hill; 2000:1288-1300
31. Nicol ME, Holdcroft A. Density of intrathecal agents. Br J Anaesth. 1992; 68: 60-63
32. National Library of Medicine. Health Services/Technology Assessment Text. Implantable infusion pumps. www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=hstat6. section.43814 (accessed 2009 Apr 21).
33. Ridley B, Rawlins P. Intrathecal baclofen therapy: ten steps toward best practice. J Neurosci Nurs. 2006; 38:72-82.
34. Deer TR, Raso LJ, Coffey RJ et al. Intrathecal baclofen and catheter tip inflammatory mass lesions (granulomas): a reevaluation of case reports and imaging findings in light of experimental, clinicopathological, and radiological evidence. Pain Med. 2008; 9:391-395
35. Medtronic. Intrathecal drug delivery: patient information for medtronic infusion systems. www.medtronic.com/your-health/brain-injury/device/our- baclofen-pump/synchromed-ii-pump/index.htm (accessed 2009 Jan 14).
36. Cooper DJ, Bergman J. Massive baclofen overdose. Crit Care Resusc. 2000; 2:195-197
37. Al-khodairy AT, Vuagnat H, Uebelhart D. Symptoms of recurrent intrathecal baclofen withdrawal resulting from drug delivery failure: a case report. Am J Phys Med Rehabil. 1999; 78:272-277 (Pubitemid 29227174)
38. Greenberg MI, Hendrickson RG. Baclofen withdrawal following removal of an intrathecal baclofen pump despite oral baclofen replacement. J Toxicol Clin Toxicol. 2003; 41:83-85 (Pubitemid 36268564)
39. Alden TD, Lytle RA, Park TS et al. Intrathecal baclofen withdrawal: a case report and review of the literature. Childs Nerv Syst. 2002; 18:522-525 (Pubitemid 36013706)
40. World Health Organization. Production. www.who.int/medicines/areas/ quality-safety/quality-assurance/production/en/index.html (accessed 2008 Oct 24).
41. Medtronic. The Clear Solution. Available through Medtronic, UC200200892bEN NP4888b.
42. Lioresal intrathecal package insert. Stein, Switzerland: Novartis Pharma; 2002.
43. American Society of Health-System Pharmacists. ASHP Discussion guide on USP chapter 797 for compounding sterile preparations. www.ashp.org/s-ashp/docs/ files/DiscGuide797-2008.pdf (accessed 2008 Oct 24).
44. Moberg-Wolff E. Intrathecal baclofen: to compound or not to compound. Presented at the 67th Annual Assembly of the American Academy of Physical Medicine and Rehabilitation. Honolulu, HI; 2006 Nov 9-12.
45. Sigg Juergen, Sonntag JC, Li J. Solubility and stability of intrathecal baclofen solutions at high concentrations: implications for chronic use in the SynchroMed infusion system. White paper. Available through Medtronic, UC200701657a EN NP7533a.